DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics Corp., announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 10,222,375 covering the company’s AIX1000 system.
The AIX1000's proprietary technology for automating the Rapid Plasma Reagin (RPR) assay represents a significant advance in testing capability for laboratories that perform serological testing for syphilis. This is the first U.S. patent issued to cover the AIX1000 system, and Gold Standard Diagnostics has exclusive rights to the patented technology. Specifically, the patent covers automated methods for performing the RPR assay, and software for result interpretation.
“This patent demonstrates key technological advances that improve the diagnosis of syphilis,” said John Griffiths, CEO of Gold Standard Diagnostics. “By combining novel approaches to automation and machine learning software, we have developed an innovative diagnostic system that provides an efficient, objective, and high-quality solution for syphilis testing in clinical laboratories.”
About the AIX100
The Gold Standard Diagnostics AIX1000® is an FDA-cleared and CE-marked in vitro diagnostic system that detects antibodies in serum obtained in individuals suspected of having syphilis.
For more information, visit https://gsdx.us/aix1000-home/.
About Gold Standard Diagnostics Corp.
Gold Standard Diagnostics, Corp. is a clinical diagnostics company based in Davis, California. The company develops, manufactures and distributes a portfolio of instrumentation and diagnostic test kits to clinical laboratories worldwide. In addition to the AIX1000, current product offerings include the Thunderbolt™ and Bolt®, open format instrumentation platforms for enzyme and chemiluminescence immunoassays, and an extensive menu of serology tests across autoimmune, infectious, and endocrine diseases. Gold Standard Diagnostics is a member of the Eurofins group of companies.